Why catalog names and paper names diverge
Catalog names are filing labels for research vials, while paper names are what a chemistry article called the molecule it tested.
Suppliers shorten, code, or group compounds so a table of contents stays readable. A code can point at a published analogue, a fragment, or a blend of two peptides that each have their own papers. The code does not carry the analytical proof. That proof is the certificate of analysis.
A few habits keep a note honest:
- Use the supplier's own name in the title, and put the receptor or sequence class in the first sentence.
- Write "described as" when the link to a paper is by chemical class. Quote a sequence only when a primary source prints it.
- Treat a blend as a blend. A co-lyophilized pair does not inherit a literature that the pair itself does not have. The CJC-1295 no DAC + Ipamorelin note is written that way.
- If two vendors use one short name for different sequences, do not merge them.
Residue Notes follows that rule on purpose. Titles stay with catalog names. Finished-drug brand names stay off the title line. GLP-3R is the worked example: the note uses the catalog name, then says which receptors the chemistry papers discuss.